glp-1 for iih Beyond weight loss: a case study and narrative review of the potential role of glucagon-like peptide-1 receptor agonists the treatment of idiopathic intracranial hypertension - Paulo NeuroOp Guru: Stopping GLP-1 therapy
Description
GLP-1 therapy is typically a long-term commitment
Indeed, it has been estimated that just 10-15% of the secreted GLP-1(7-36) NH2 reaches the systemic circulation (117), with some authors reporting meager peripheral meal-induced changes in both healthy and diabetic people (118)
Brain regulation of appetite is one of the more promising avenues of reducing obesity and diabetes
Current evidence supports indefinite use for patients who tolerate the medication well and continue to benefit from it
Fatigue during GLP-1 transitions is common and manageable but should not be ignored
Q: How often should I see the dentist while on GLP-1 medication
